HUMA
Humacyte Inc
NASDAQ: HUMA · HEALTHCARE · BIOTECHNOLOGY
$0.84
+2.66% today
Updated 2026-04-30
Market cap
$178.93M
P/E ratio
—
P/S ratio
87.79x
EPS (TTM)
$-0.26
Dividend yield
—
52W range
$1 – $3
Volume
6.7M
Humacyte Inc (HUMA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.19M | $1.49M | $1.26M | $1.56M | $0.00 | $0.00 | $2.04M |
| Revenue growth (YoY) | — | -75.9% | -15.3% | +23.9% | -100.0% | — | — |
| Cost of revenue | $75.60M | $54.08M | $61.34M | $8.26M | $76.55M | $7.19M | $17.05M |
| Gross profit | $-69.42M | $-52.59M | $-60.08M | $-6.69M | $-76.55M | $-7.19M | $-15.01M |
| Gross margin | -1122.0% | -3527.0% | -4756.8% | -427.5% | — | — | -736.5% |
| R&D | $75.60M | $54.08M | $61.34M | $63.26M | $76.55M | $88.60M | $69.30M |
| SG&A | $16.27M | $11.86M | $21.02M | $22.88M | $23.39M | $25.80M | $31.17M |
| Operating income | $-85.69M | $-64.60M | $-81.21M | $-84.58M | $-100.05M | $-114.40M | $-107.44M |
| Operating margin | -1385.0% | -4332.7% | -6429.8% | -5404.3% | — | — | -5271.7% |
| EBITDA | $-78.94M | $-56.25M | $-72.97M | $-76.37M | $-96.46M | $-132.23M | $-100.09M |
| EBITDA margin | -1275.9% | -3772.6% | -5777.3% | -4879.7% | — | — | -4911.3% |
| EBIT | $-85.69M | $-64.60M | $-81.21M | $-84.58M | $-104.18M | $-139.42M | $-107.44M |
| Interest expense | $2.30M | $2.20M | $4.35M | $6.20M | $6.60M | $9.28M | $11.25M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-85.42M | $-66.52M | $-26.48M | $-11.96M | $-110.78M | $-148.70M | $-40.83M |
| Net income growth (YoY) | — | +22.1% | +60.2% | +54.8% | -825.8% | -34.2% | +72.5% |
| Profit margin | -1380.7% | -4461.7% | -2096.4% | -764.5% | — | — | -2003.6% |